Intriguing new data demonstrate that scleroderma patients with anti-centromere antibodies have a lower risk of cancer than that expected in the general population and that scleroderma patients with autoantibodies against both POLR3 and the large subunit of RNA polymerase I (RPA194) have a lower frequency of cancer than those with anti-POLR3 alone [3, 6]. The gene discussed is POLR1A; the disease is scleroderma.